1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsResearch, Education, and Outreach on Botanical Natural Products is sponsored by Food and Drug Administration (FDA). This single-source cooperative agreement provides continued support for research, education, and outreach focused on botanical natural products found in foods, dietary supplements, and cosmetics marketed in the U.
Get alerted about grants like this
Get emailed when new opportunities from “Food and Drug Administration (FDA)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Research, Education, and Outreach on Botanical Natural Products Research, Education, and Outreach on Botanical Natural Products Agency: Food and Drug Administration Assistance Listings: 93. 103 -- Food and Drug Administration Research Last Updated: July 22, 2026 View version history on Grants.
gov The purpose of this funding opportunity is to provide continued support to: (1) assist in the identification and development of a prioritized list of botanical ingredients based on safety concerns, trends and knowledge of botanical ingredients in foods, dietary supplements, and cosmetics marketed in the U.S.; (2) acquire, validate and characterize authenticated reference materials, including raw and processed plant materials and purified natural products of relevance to FDA for evaluation of safety; (3) exchange technical and scientific information, methods and reference material with FDA scientists and other stakeholders; (4) collaborate with FDA scientists in research areas of mutual interest; (5) coordinate scientific workshops, training and conferences on botanical topics of public health relevance to address high priority science and research needs.
Only the following applicant is eligible to apply for this single source funding: The University of Mississippi Grantor contact information Office of Acquisitions and Grants Services (OAGS) Email: patrick. johnson@fda. hhs.
gov patrick. johnson@fda. hhs.
gov File name Description Last updated RFA-FD-26-011. pdf NOFO_Research, Education, and Outreach on Botanical Natural Products Jul 22, 2026 09:57 PM UTC Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Only the University of Mississippi is eligible to apply for this single-source funding. Confirm the full requirements in the official notice before applying.
The current listing shows up to $5,100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Research, Education, and Outreach on Botanical Natural Products are due August 21, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research, Education, and Outreach on Botanical Natural Products is funded by Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Mississippi. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Minor Use Minor Species Development of Drugs (R01) (PAR-24-216) is sponsored by U.S. Food and Drug Administration (FDA) / National Institutes of Health (NIH). This grant supports the development and potential approval of new animal drugs for uncommon diseases (minor uses) in major species or to treat minor species. It covers routine safety, effectiveness, manufacturing, and toxicology studies.
Minor Use Minor Species Development of Drugs (R01) is sponsored by U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM). This grant supports the development and potential approval or conditional approval of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys, and chickens) or to treat minor species.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Missouri's Department of Agriculture has reopened its Urban Agriculture Cost-Share Grant — reimbursing 75% of project costs up to $10,000, with applications due September 15, 2026. A companion Food Insecure Cost-Share Grant closes August 26. Here is how these small, fast state grants work, who qualifies under the Census 'urban area' definition, and how to layer them with the federal USDA Urban Agriculture and Innovative Production program for a durable urban-farming funding strategy.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read article